Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04162795 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies
A Phase 4 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 468
- Enrollment target
NCT04162795 is a Phase 4 study that has completed, run by Bayer. The registered enrollment target is 468 participants.
The verdict
NCT04162795, a Phase 4 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 468 participants
- Enrollment target
Study Summary
In this study, researchers were primarily interested in evaluating the level of agreement of cooling sensation provided by this chewable, flavored, allergy medicine. Participants joining this study received one test drug tablet and were asked to chew completely before swallowing the drug. A questionnaire was used to collect the feedback from participants. The study involved only one (1) visit and participant stayed in this study for about 60-75 minutes to evaluate the cooling sensation as well as other sensory attributes perceived in the mouth, nose and throat.
Interventions
- DRUG Loratadine (Claritin, BAY76-2211)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 468 participants |
| Start Date | 2019-11-12 |
| Est. Completion | 2019-11-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04162795
The ClinicalTrials.gov registry entry for NCT04162795 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 468 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Loratadine (Claritin, BAY76-2211) is the first listed.
NCT04162795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04162795 about?
NCT04162795 is a clinical study titled "A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies". In this study, researchers were primarily interested in evaluating the level of agreement of cooling sensation provided by this chewable, flavored, allergy medicine. Participants joining this study received one test drug tablet and were asked to chew completely before swallowing the drug. A question...
What is the current status of trial NCT04162795?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 468 participants. The study started on 2019-11-12. Estimated completion is 2019-11-13.
What interventions are being tested in trial NCT04162795?
The interventions under investigation include: Loratadine (Claritin, BAY76-2211) (DRUG).
Who is sponsoring clinical trial NCT04162795?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.